Bausch + Lomb Corporation (TSX:BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of PreserVision® AREDS 2 Formula mini soft gels with OCUSorb™. This product is the only AREDS 2 eye vitamin with the OCUSorb formulation. Offering a proprietary composition of lutein and zeaxanthin, OCUSorb has been clinically shown to provide superior absorption of these nutrients into the body as compared to the original PreserVision AREDS 2 mini soft gel formula.
Citigroup Maintains Neutral on FinVolution Gr, Lowers Price Target to $3.27
Citigroup analyst Julia Cheung maintains FinVolution Gr (NYSE:FINV) with a Neutral and lowers the price target from $7.27 to $3.27.
